did not demonstrate any relationship to the level of expression of either FcγRI or FcγRIIa. Therefore, we hypothesized that the variability in CRP binding may correspond to the single nucleotide polymorphism in human FcγRIIA. This polymorphism produces a single amino acid difference -arginine (R) or histidine (H) -at position 131 (12) . These FcγRIIa alleles show a variability in binding of human IgG2 (13) and murine IgG1 (14) . The H-131 allele is the only human FcγR to bind human IgG2 efficiently (15) .
In this article, we present the first direct experimental evidence that FcγRIIa is the functional high-affinity receptor for CRP on peripheral blood PMN and monocytes. Furthermore, CRP binding to monocytes and PMN was clearly evident in cells from donors with the R-131 allele of FcγRIIa with only minimal binding to cells from donors homozygous for the H-131 allele. Binding of CRP to FcγRIIa-R-131 was inhibited by mAb 41H16, which is specific for the R-131 form of FcγRIIa. CRP binding to monocytes from H-131 homozygous donors could be induced after culture in IFN-γ and upregulation of FcγRI expression. Pronase treatment of monocytes or PMN to activate FcγRIIa did enhance CRP binding, but did not abrogate the differences in binding of CRP to the R-131 and H-131 alleles of FcγRIIa. These data not only provide direct genetic evidence for FcγRIIa as the major, high-affinity receptor for CRP in human phagocytes, but they also demonstrate the importance of both the cytokine environment and allelic variations in receptor structure in determining the host response to CRP. These findings may have important consequences in studies of host defense and risk for autoimmunity.
Methods
Reagents and antibodies. Human CRP was purified from human pleural fluids exactly as previously described (16) . The purity of the preparation was determined by 12% SDS-PAGE. No contaminating proteins were detected on overloaded gels. Essentially Ig-free BSA, HBSS without calcium or magnesium (HBSS -), and pronase were purchased from Sigma (St. Louis, Missouri, USA). Recombinant human IFN-γ was provided by Genentech Inc. (South San Francisco, California, USA). The anti-CRP mAb 2C10 (a mouse IgG1 mAb) was generously provided by Larry Potempa (ImmTech International Inc., Evanston, Illinois, USA) and was FITC conjugated in our laboratory. A control mouse IgG1 was purchased from Sigma and was used as a control for the 2C10 mAb. The anti-FcγRII mAb 41H16 was generously provided by Thomas Zipf (University of Texas Cancer Center, Houston, Texas, USA) (17) . Isotype controls for mIgG2a were obtained from Sigma and PharMingen (San Diego, California, USA). Anti-FcγR antibodies were purchased as follows: FITC anti-CD64 (mAb 10.1), FITC anti-CD16 (mAb 3G8) from PharMingen; anti-CD64 (mAb 32.2), anti-CD32 (mAb IV.3, IgG, and Fab), and anti-CD16 (mAb 3G8) from Medarex Inc. (Annandale, New Jersey, USA); and phycoerythrin (PE) anti-CD32 (mAb C1KM5) from Caltag Laboratories Inc. (Burlingame, California, USA). Lymphocyte markers were anti-CD56 (natural killer (NK)) (Becton-Dickinson Immunocytometry Systems, San Jose, California, USA), anti-CD19 (B cells), and anti-CD3 (T cells) (Caltag Laboratories Inc.). PE-conjugated F(ab′) 2 goat anti-mouse IgG (PE-GAM) and PE-conjugated F(ab′) 2 goat anti-rabbit IgG were from Caltag Laboratories Inc. F(ab′) 2 goat antimouse IgG (GAM) was from TAGO Inc. (Burlingame, California, USA). A rabbit anti-CRP antibody was prepared in our laboratory, and IgG was purified by protein A affinity chromatography.
Figure 1
CRP binding to human monocytes and PMN is FcγRIIa allele-specific. Human monocytes and PMN from genotyped donors were isolated from peripheral blood by gradient separation using Mono-Poly Resolving Medium. Cells were washed in ice-cold PAB and incubated in the presence of CRP for 60 minutes on ice. After 2 washes, bound CRP was detected by flow cytometry using mAb 2C10 and PE-GAM. Results are expressed as the change in GMFI. Data were analyzed by Student's paired t-test and two-tailed P values were calculated using GraphPad Prism software. The P values for RR versus HH, RR versus RH, and RH versus HH monocytes were 0.004, 0.001, and 0.015, respectively. The P values for RR versus HH, RR versus RH, and RH versus HH neutrophils were 0.008, 0.005, and 0.018, respectively.
Genotyping of FcγR alleles. Genomic DNA was extracted from EDTA anticoagulated whole blood (Gentra Systems Inc., Plymouth, Minnesota, USA). For FcγR genotype determinations, we used allele-specific PCR reactions to characterize the presence or absence of the H-131/R-131 alleles of FcγRIIA, the NA1/NA2 alleles of FcγRIIIB, and the F176/V176 alleles of FcγRIIIA (18, 19) . For the FcγRIIA alleles, a forward PCR primer was used to bind to a sequence in intron 4 that is unique to the FcγRIIA gene together with either H-131-or R-131-specific reverse primers as we have reported previously (19) . For the FcγRIIIB alleles, we used a forward primer that binds to a sequence in intron 1 that is unique to the FcγRIIIB gene together with both NA1-and NA2-specific reverse primers in a multiplex PCR reaction. For the FcγRIIIA alleles, we used a forward FcγRIIIA-specific PCR primer that binds to a sequence in exon 4 together with either F159-or V159-specific reverse primers as we have reported previously (18) .
Peripheral blood cells. Monocytes and neutrophils were obtained from peripheral blood of healthy volunteers by gradient separation using Mono-Poly Resolving Medium (ICN Pharmaceuticals, Aurora, Ohio, USA). Cells were washed twice in HBSS -before analysis for CRP binding. To increase expression of FcγRI, peripheral blood mononuclear cells were isolated, resuspended in complete medium (RPMI-1640 with 10% FCS and 50 µg/mL gentamicin), and then cultured for 48 hours in the presence of 200 U/mL recombinant human IFN-γ before analysis for FcγR expression and CRP binding.
In some experiments, isolated monocytes and PMN were incubated at a concentration of 5 × 10 6 cells/mL with 50 µg/mL pronase for 30 minutes at 37°C before analysis of CRP binding.
FcγRIIIa-bound CRP was assessed on peripheral blood NK cells by multicolor flow cytometry using anti-CD56 to positively identify the NK cells (18) . The CD56-positive cells were also shown to express CD16. In some experiments, anti-CD19 and anti-CD3 were included to exclude B and T lymphocytes.
CRP-binding assay. Cells were washed twice in PBS containing 0.1% BSA and 0.05% sodium azide (PAB). Cells (3-10 × 10 5 per sample) were incubated in CRP-containing PAB for 1 hour on ice. Cells were washed twice with 1 mL PAB and then incubated on ice with 4 µg/mL mAb 2C10 for 30 minutes. Cells were washed twice as before and then incubated for 30 minutes with 1 µg per 10 6 cells of PE-GAM, PE anti-CD32, FITC anti-CD16, or FITC anti-CD64. Cells were washed and resuspended in PAB for analysis by flow cytometry. CRP binding was also determined using IgG rabbit anti-CRP and PE goat anti-rabbit IgG.
Anti-FcγRIIa mAb blocking of CRP binding. Washed anticoagulated whole blood was prepared as described (20) . Aliquots of the washed blood were incubated with the anti-FcγRIIa mAb 41H16 (17) or with a mIgG2a isotype control (clone UPC-10; Sigma) for 15 minutes at 4°C. CRP (100 µg/mL) was added, and the incubation was continued for an additional 60 minutes. After 2 washes, bound CRP was detected with the anti-CRP mAb 2C10-FITC.
Flow cytometry. Cells were analyzed using a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems). Dead cells were excluded from analysis by forward and side scatter. In all measurements of CRP binding, background binding of 2C10 and PE-GAM has been subtracted. Values are reported as the change in geometric mean fluorescence intensity (∆GMFI). Data were analyzed using GraphPad Prism software (GraphPad Software for Science Inc., San Diego, California, USA). Error bars denote the SEM as determined based on n samples for each concentration of CRP.
Analysis of intracellular Ca 2+ concentrations. Indo-1, a fluorescent dye with spectral properties that change with the binding of free Ca 2+ , was used to measure changes in intracellular calcium concentrations as we have described (21, 22) . PMN were incubated at 37°C for 15 minutes with 5 µM Indo-1 acetoxymethylester (AM). After load- ing, the cells were washed once with modified PBS (containing 5 mM KCl and 5 mM glucose) and maintained at 25°C in the dark. In some samples, an aliquot of cells (at a concentration of 10 7 cells/mL) was incubated with anti-CD32 mAb IV.3 Fab for 5 minutes at 37°C followed by 1 wash at room temperature. The cells were then resuspended to 5 × 10 6 cells/mL in modified PBS and then warmed to 37°C for 5 minutes in modified PBS, 1.1 mM Ca 2+ , and 1.6 mM Mg 2+ before analysis.
Indo-1 fluorescence analysis was performed on a spectrofluorometer (SLM 8000C; Spectronic Instruments Inc., Rochester, New York, USA). Excitation at 355 nm was provided by a xenon arc lamp and a monochromator, while emission at 405 and 490 nm were simultaneously monitored with 2 monochromators and photo multiplier tubes. A corresponding stimulus was injected into each cuvette at 60 seconds without interruption of acquisition. Constant temperature (37°C) and stirring were maintained throughout each experiment. Each sample was individually calibrated for both maximum and minimum Indo-1 fluorescence by sequential addition of Triton X-100 and EDTA, and the 405/490 nm ratio was converted to [Ca 2+ ] as previously described (21, 22) .
Results

Analysis of CRP binding to human monocytes and PMN.
Peripheral blood monocytes and PMN from healthy volunteers of known FcγRIIA genotype were tested for CRP binding using a flow cytometric assay. CRP binding to monocytes from R-131 homozygotes and R/H-131 heterozygotes was dose dependent and saturable at approximately 100 µg/mL of CRP. Monocytes from R-131 homozygotes bound CRP with an apparent K d of 27 µg/mL (2.4 × 10 -7 M), whereas monocytes from heterozygotes bound CRP with an apparent K d of 77 µg/mL (7.0 × 10 -7 M) (Figure 1a) . The binding avidity of CRP for monocytes from heterozygous donors compared with monocytes from R-131 homozygous donors was thus decreased by 65%. CRP binding to monocytes from H-131 homozygotes was not detected. The presence of FcγRI and FcγRII on monocytes was confirmed by staining with anti-CD64 and anti-CD32 mAb. Consistent with previous reports of Guyre et al. (23) who found 15,000-35,000 binding sites per cell for anti-CD64, expression of FcγRI on monocytes was low. Levels of FcγRIII on monocytes were also low.
Similarly, CRP bound to human PMN from R-131 homozygous and R/H-131 heterozygous donors in a dose-dependent manner with saturation at approximately 100 µg/mL CRP (Figure 1b) . CRP bound to PMN from R-131 homozygotes with an apparent K d of 33 µg/mL (3.0 × 10 -7 M); whereas it bound to PMN from R/H-131 heterozygous donors with an apparent K d of 107 µg/mL (9.7 × 10 -7 M). This represents a 70% decrease in CRP-binding avidity for PMN from R/H-131 heterozygotes compared with PMN from R/H-131 heterozygotes. Once again, no binding of CRP was detected to PMN from H-131 homozygotes. The presence of FcγRII and FcγRIII on PMN was confirmed by staining with anti-CD32 and anti-CD16 mAb. There were no consistent differences in the levels of all 3 classes of FcγR on monocytes and PMN between R-131 homozygous, R/H heterozygous, and H-131 homozygous donors, consistent with previous data (17) .
Because mouse IgG1 could potentially be differentially bound to the 2 allelic forms of FcRII, the preferential binding of CRP to the R allotype was verified using an independent binding assay. We have previously shown that the binding of rabbit IgG is insensitive to the H-131/R-131 alleles of FcγRIIa (24) . Accordingly, we used a rabbit polyclonal anti-CRP antibody as the primary detecting reagent, and a PE-conjugated goat antirabbit IgG was used as the labeled secondary antibody. The preferential binding of CRP to the R-131 allotype was confirmed (Figure 2a) . As a comparison, the binding of mAb 2C10-FITC to neutrophils from the same donors is shown in Figure 2b . The apparent level of binding of CRP to both FcγRIIa alleles is higher using the rabbit polyclonal anti-CRP because of a more effi-
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The (17) . Preincubation of whole blood with a saturating dose of mAb 41H16 -but not an isotype controlcompletely blocked the binding of CRP to PMN and monocytes from R-131 homozygous donors (Figure 3 ). We and others have previously shown that mAb IV.3, which completely blocks IgG binding, does not inhibit CRP binding (7, 9) . However, mAb IV.3 is insensitive to the H-131/R-131 polymorphism. Together, these results suggest that CRP binding to human peripheral blood monocytes and PMN requires the presence of the FcγRIIa R-131 phenotype.
CRP induces an intracellular Ca 2+ transient in an FcγRIIa allele-dependent manner.
To determine the functional consequences of the FcγRIIa alleles on neutrophil activation by CRP, we analyzed the ability of CRP to induce an intracellular Ca 2+ transient. We and others have shown that engagement and cross-linking of FcγRIIa on human PMN results in a rapid and transient rise in intracellular Ca 2+ that is derived from intracellular stores (22) . Accordingly, isolated human PMN from donors homozygous for either H or R were loaded with the Ca 2+ -sensitive dye Indo-1. After assessment of resting Ca 2+ levels, CRP was added to the cells. A rapid and transient elevation in intracellular Ca 2+ was observed in PMN from R-131 homozygous donors, but none was observed in H-131 homozygous donors (Figure 4a ). To verify that the PMN from the H-131 homozygous donor were functionally competent, separate aliquots of cells from all donors were stimulated with either 10 -7 M fMLP (results not shown) or with the anti-FcγRIIa mAb IV.3 Fab and F(ab′) 2 GAM (Figure 4b) , and comparable Ca 2+ transients were observed. Finally, CRP binding to the Indo-1-loaded PMN was confirmed by flow cytometric analysis of aliquots of the cell suspensions which had been removed after completion of the Ca 2+ transient. These results demonstrate that the R allele-specific binding of CRP is functionally relevant and results in the initiation of intracellular signaling events.
Analysis of CRP binding to FcγRIII. NK cells express FcγRI-IIa, and 2 allelic forms of this receptor have been described with either phenylalanine (F) or valine (V) at position 176. To determine if CRP can bind to either of the alleles, whole blood from donors homozygous for either F176 or V176 were analyzed. NK cells were identified by a combination of characteristic light scatter properties and CD56 expression as we have described (18) . No CRP binding was detectable on the CD56-positive cells from donors homozygous for either FcγRIIIa allele (Figure 5, a and b) . Expression of FcγRIIIa on the CD56-positive cells was verified with an anti-CD16 mAb (Figure 5c ). As a positive control, each donor was either R-131/R-131 or R-131/H-131 with respect to FcγRIIa, and binding of CRP to monocytes and PMN was verified. PMN express the glycosylphosphatidylinositolanchored receptor, FcγRIIIb, which has an allelic polymorphism, designated as NA1/NA2. PMN from all donors shown in Figure 2 expressed high levels of FcγRIIIb, measured using mAb 3G8. Little or no CRP binding was observed using PMN from H-131 homozygotes, which suggests that CRP does not bind to FcγRI-IIb. To eliminate possible allele-specific binding of CRP to FcγRIIIB, the genotypes of the H-131 homozygotes, with respect to the NA1 and NA2 alleles of FcγRIIIb, were determined. Homozygous individuals of each type as well as heterozygous individuals were included in the H-131 homozygotes shown. These results indicate that CRP does not bind to either FcγRIIIb allele.
CRP binding to H-131/H-131 monocytes is enhanced by treatment with IFN-γ.
Because we had previously demonstrated that CRP binds to FcγRI in transfected COS cells (8) , it was expected that CRP would bind to FcγRI on monocytes. However, as shown in Figure 1a (25, 26) . It has been shown that treatment of monocytes and cell lines with pronase can enhance IgG binding. We therefore tested the effect of pronase treatment of human monocytes and PMN on CRP binding. CRP binding to R-131/R-131 and R-131/H-131 monocytes and PMN was markedly increased after pronase treatment (data not shown). However, CRP binding to PMN and monocytes from FcγRIIa H-131/H-131 donors was only slightly enhanced. Similar results were obtained using the rabbit anti-CRP-detecting antibody. Receptor numbers, excluding FcγRIIIb were not changed by pronase treatment as determined by mAb staining. FcγRIIIb, which is known to be pronase sensitive, was largely removed. Therefore activation of PMN and monocytes at inflammatory sites does not alter the selectivity of CRP binding for the R-131 form of FcγRIIa.
Discussion
CRP is the prototypic acute phase protein in humans (1) . In animal models, CRP has been shown to protect against bacterial infection (26, 27) , endotoxin shock (28), pulmonary inflammation (29) , and autoimmune disease (30) . CRP binds to bacterial polysaccharides (31), damaged membranes (32, 33) , and nuclear antigens (34, 35) . Its functional activity is believed to be mediated by complement activation and interaction with receptors on phagocytic cells. Monocytes, neutrophils, and myeloid cell lines have high-and low-affinity receptors for CRP (9) . The relationship between the CRP receptors and FcγR had been controversial for many years. Several years ago, we determined that CRP binds with low affinity to FcγRI (7, 8) , and more recently, we found that CRP binds with high affinity to FcγRI-Ia (11) . Results using transfected COS cells and cell lines indicate that FcγRI and FcγRII are the major leukocyte receptors for CRP. This conclusion is supported by the inability of CRP to bind to peritoneal macrophages and PMN from mice lacking all 3 types of FcγR (36) .
Previous studies of CRP binding and activation of human peripheral blood leukocytes have produced contradictory results. We observed that the level of CRP binding to human monocytes and PMN differed among individuals. As allelic differences in FcγRIIa, FcγRIIIa,
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The Consistent with the conclusion that the FcγRIIa-R-131 allele is the major high-affinity receptor for CRP, binding to FcγRIIa-R-131 on peripheral blood leukocytes was completely inhibited by the mAb 41H16. This mAb binds to the R-131 allele but not the H-131 allele of FcγRIIa, and it also blocks the binding of IgG to FcγRIIa-R-131 (17) . Thus, the site of CRP binding to FcγRIIa is closely related to the site at which IgG binds to FcγRIIa. The anti-CD32 mAb IV.3, which blocks aggIgG binding, does not block CRP binding to cell lines (7, 9) . However, as this mAb is not sensitive to the H-131/R-131 polymorphism, it must recognize a distinct but perhaps overlapping epitope on FcγRIIa relative to mAb 41H16. Therefore, the site of CRP binding to FcγRIIa is closely related to -but not identical tothe site at which IgG binds to FcγRIIa.
The R-131 allele of FcγRIIa is associated with increased susceptibility to infection with certain encapsulated bacteria (37, 38) . It has been postulated that these associations are the result of the decreased binding of IgG2 to the R-131 allele (39). IgG2 is the major subclass of antibody produced in response to polysaccharide antigens, including capsular polysaccharides of Streptococcus pneumoniae and Hemophilus influenza in children (40) . CRP binds to several encapsulated bacteria including S. pneumoniae (41) and H. influenza (42) . It is attractive to speculate that CRP fills this immunological niche and provides partial protection from infection in individuals bearing the R-131 allotype of FcγRIIa.
Analysis of the relative binding avidities of CRP to monocytes and PMN demonstrates a lower avidity of binding to cells from heterozygous H-131/R-131 donors as compared with cells from R-131 homozygotes. Thus, CRP binding to FcγRIIa is dependent on the level of expression of the FcγRIIa R-131 allotype. One possible explanation for the difference in avidity of CRP binding to cells from R-131/R-131 and R-131/H-131 individuals is that CRP binding to FcγRIIa is cooperative. The stoichiometry of CRP interaction with FcγRIIa has not been determined. CRP is a pentamer with 5 identical subunits potentially capable of interacting with FcγR. It is possible that CRP can interact with multiple FcγR leading to enhanced avidity. The binding avidities of CRP for monocytes from R-131 homozygous and R-131/H-131 heterozygous donors were 24 and 75 µg/mL, respectively. These values are in the range of CRP concentrations present in sera from patients with mild to moderate acute phase responses (43) .
FcγRIIa is unique among receptors using the immunoreceptor tyrosine activation motif (ITAM). Unlike other Fc receptors, the B-cell receptor complex and the CD3 complex, FcγRIIa is a single-chain receptor that can bind ligands and induce intracellular signaling events with an ITAM motif in the cytoplasmic domain (44) . Responses induced by the crosslinking of this receptor include initiation of the oxidative burst, degranulation, cytokine production, and phagocytosis. The ability of CRP to induce a Ca 2+ transient in PMN, which is required for many FcγRIIa-induced functions, suggests that CRP binding to FcγRIIa-R-131 mimics binding of crosslinked IgG. These data suggest that CRP, because of its pentameric structure, can crosslink FcγR on the cell surface. In vivo, CRP forms aggregates with various antigens because of its Ca 2+ -dependent ligand-binding sites that further enhance its ability to cross-link cell surface FcγR.
Although we previously demonstrated CRP binding to FcγRI on monocytic cell lines and transfected COS cells, we found reduced CRP binding to leukocytes from FcγRIIa H-131 homozygous donors. However, peripheral blood PMN do not express FcγRI, and monocytes express FcγRI at low levels. The levels of FcγRI on both monocytes and PMN are increased by cytokines such as IFN-γ (23). Increased binding of CRP to monocytes from H-131/H-131 donors after culture in IFN-γ was observed. Thus, the lack of CRP binding to FcγRI in these cells is related to the low affinity of CRP for FcγRI as well as the low level of expression of FcγRI in resting monocytes and PMN. In these experiments, we also observed enhanced CRP binding to FcγRIIa after pro- tease treatment of cells, which suggests that conditions at inflammatory sites may upregulate CRP binding to both receptors. A similar role for inflammatory cytokines and proteolytic enzymes at sites of acute inflammation has been proposed as a mechanism for upregulation of immune complex binding to inflammatory cells (45) . However, the differences in allotypes seen in resting cells were not eliminated by activation. Additional studies will be needed to establish the relative importance of CRP binding to FcγRI and FcγRIIa during the acute phase response and at inflammatory sites where levels of FcγRI may be greatly elevated.
